In a related room, Schoeffel and colleagues evaluated the effects of PPI therapy on physiological state disturbances in patients with EE treated with pantoprazole (40 mg daily) or omeprazole (20 mg daily) for 6 weeks. Using a validated GERD questionnaire, they found that patients treated with either PPI had melioration in gastrointestinal and physical condition scores compared with touchstone scores, with pantoprazole exhibiting a slight but statistically significant vantage over omeprazole. Unfortunately, these data are limited by several composition sketch issues. These include concerns that the doses of pantoprazole and omeprazole compared may not be physiologically cognition, that the reported differences reflect only the number one 2 weeks of therapy, and that they may be mental object to a smorgasbord bias because the results reported apply only to those EE patients who reported period disturbances at criterion (31% to 33% for each group) — so, the durability and clinical relevance to the broader conception of GERD patients cannot be absolutely determined from these results.
It has become increasingly popular to use high doses of twice-daily therapy for the extraesophageal manifestations of GERD — but this cognition is not based on definitive info. Park and colleagues tested this view in an open-label prospective circle field of study in which patients with laryngoscopy findings suggestive of GERD were treated with a heterogeneousness of acid growing regimens (lansoprazole* 30 mg given twice daily, omeprazole* 20 mg given twice daily + ranitidine* 300 mg at bedtime, or nexium 20 mg given once daily) for 2 months. Outcome was defined as > 50% transformation in ear/nose/throat symptoms, and nonresponders in the once-daily PPI chemical group were treated and observed for an additional 2 months with the twice-daily PPI therapy. Patients in both of the twice-daily PPI groups (with and without ranitidine) had transformation in ear/nose/throat symptoms of more than 50%.